Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of intravesical versus intravenous camrelizumab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer
ChiCTR2000035762Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Complete response rate and Recurrence-free survival. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2000035762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035762.